The FDA just changed the game for peptides. April 2026 The FDA is reviewing Category 2 peptides for potential removal from restricted status. Full approval for some peptides may be Nine Anticipated FDA Approvals for January 2026 Guideline Central FDA May Reverse Ban on 14 PeptidesWhat It Means for Your Beauty Routine Allure FDA Action Update, January 2026: Approvals, Acceptance, and Clearance NeurologyLive Clinical Neurology News and Neurology Expert Insights GHK Cu Mr & Mrs Peptides The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what